|
|||||||||
|
|
|
|
|
|
|
|
|
|
|
Blood, 15 July 2006, Vol. 108, No. 2, pp. 411-412.
Boosting functional hematolymphopoiesis in humanized miceUNIVERSITY OF PITTSBURGH CANCER INSTITUTE
Enhancing human hematolymphopoiesis and especially T-lymphopoiesis remains an important goal for optimizing the current humanized immunodeficient mouse models. Yang's team reports an improved human fetal thymus/liver–implanted immunodeficient mouse model in which a striking increase of the overall hematolymphopoiesis with significantly enhanced immune functions can be achieved via a simple intravenous infusion of autologous human fetal liver CD34+ cells.
In this issue of Blood, Lan et al report a small modification but a big improvement over the previous Thy/Liv model. The authors cleverly combined the infusion of autologous CD34+ human fetal liver cells with human fetal Thy/Liv implants5 in NOD/SCID mice (see the figure). In this model, they were able to achieve a very high degree of engraftment (up to 40% in blood) of human T cells along with other hematopoietic lineages (B and myeloid cells). Moreover, the human cells massively populated the secondary lymphoid organs, and the formation of white pulplike structures was observed in the spleen. In particular, human dendritic cells (both myeloid and plasmacytoid) were present only in the spleen and lymph nodes of CD34+ cell-infused Thy/Liv mice, and human immunoglobulin was also significantly increased in these mice. Most impressively, the human T-cell immunity in vivo was evidenced by rejection to a porcine skin xenograft in the CD34+ cell–infused Thy/Livgroup but not the Thy/Liv-only group. Notably, the infusion of the human CD34+ cells did not seem to just serve as"add-on" engraftment to the basal human hematopoiesis and lymphopoiesis achieved by the human fetal thymus/liver implants alone. Rather, the infused CD34+ cells, even with a limited number (1 to 5 x 105 per animal), had a profound synergistic effect on the establishment of human lymphohematopoiesis in the mice. One possible cause behind the dramatic effects, as the authors point out, is that the infused CD34+ cells may equip the microenvironment with some essential immune cellular elements such as dendritic cells in the secondary lymphoid organs for a robust T-cell response to antigens.
Given the heterogeneous nature of the infused CD34+ cells, however, mechanisms for the high T-cell yield need to be further elucidated. The effective process is likely multifactorial: for example, besides hematopoietic stem/progenitor cells, some facilitating cells in the bulk CD34+ cells may also play important roles in contributing to the engraftment. In addition, an optimal cell dosage or ratio between the infused cells and implanted tissues required for the maximal effect remains to be determined. Nonetheless, although further improvements are needed and the biologic basis of the model remains to be determined, these authors have clearly made an important step toward optimal human hematolymphopoiesis in the mice, thereby allowing investigators to approach a broader set of biologic and preclinical issues on human hematopoietic stem cell repopulation, immune reconstitution, infection, vaccine development, autoimmunity, and transplant tolerance.  References
  CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati What's this?
Related Article in Blood Online:
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
 |
 |
 |
|||||||
 |
 |
 |
 |
 |
 |
 |
 |
||
| Copyright © 2006 by American Society of Hematology Online ISSN: 1528-0020 | |||||||||
2mnull, NOD/SCID/
cnull, and Rag2null/
